^
Association details:
| Biomarker: | KRAS wild-type + BRAF V600E |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
Excerpt:
This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer...Per genomic sequencing, her tumor was found to be a KRAS wild-type and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib.
Secondary therapy:
gemcitabine + albumin-bound paclitaxel
DOI:
10.1101/mcs.a006108
